Blue Wave Therapeutics is pleased to announce the appointment of Barbara Amoroso, MD, PhD, as our Chief Medical Officer.

Barbara brings more than 25 years of international experience in oncology, hematology, and clinical development across both academic and industry settings. Throughout her career, she has held senior leadership positions in global pharmaceutical and biotechnology companies, contributing to the advancement of innovative therapies from early clinical development through later-stage programs.

Her expertise spans clinical trial design and execution, regulatory interactions, medical strategy, and translational medicine. Importantly for Blue Wave Therapeutics, Barbara has also been involved in the development of radioligand therapies and possesses valuable experience in oncology indications that are highly relevant to our current and future programs, including glioblastoma.

As we continue to advance our ARAspheres™ platform and build the next generation of precision radiotherapies, Barbara’s scientific, clinical, and strategic leadership will be an important asset to our team.

We are delighted to welcome Barbara to Blue Wave Therapeutics and look forward to working together to accelerate the development of innovative therapies for patients with cancers that continue to face significant unmet medical needs.

Please join us in welcoming Barbara to the team.